Kite’s CAR-T Therapy Produces Durable Remission in DLBCL, Study Finds – AJMC.com Managed Markets Network
|
Kite's CAR–T Therapy Produces Durable Remission in DLBCL, Study Finds
AJMC.com Managed Markets Network The research, to be published in Molecular Therapy, followed 7 evaluable patients with relapsed DLBCL, a type of non-Hodgkin lymphoma (NHL), who received the anti-CD19 CAR–T cells. Of these patients, 5 demonstrated complete remission (CR), and in 4 … |
